SCHEMBL25847908

SCHEMBL25847908

C=C1CCC(n2nc(-c3ccc(C(C)(C)C)cc3)n(C)c2=O)C(=O)N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.36
▸ KDM4E B2RXH2 4/20 0.36
▸ HPGD P15428 3/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ POLB P06746 1/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ APOBEC3G Q9HC16 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ LMNA P02545 1/20 0.34
▸ XBP1 P17861 1/20 0.34
▸ ALOX12 P18054 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ SIGMAR1 Q99720 2/20 0.34
▸ TMEM97 Q5BJF2 1/20 0.34
▸ DDB1 Q16531 3/20 0.33
▸ CRBN Q96SW2 3/20 0.33
▸ MAPT P10636 1/20 0.31
▸ HSD11B1 P28845 1/20 0.31
▸ GABRA1 P14867 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23593989 0.89 CRBN (0.44) ALDH1A1KDM4EHPGDHSD17B10POLB
SCHEMBL26138573 0.86 CRBN (0.40) ALDH1A1TDP1DDB1CRBN
SCHEMBL20436926 0.77 DDB1 (0.35) DDB1CRBN
SCHEMBL24891103 0.77 CRBN (0.47) ALDH1A1TDP1DDB1CRBN
SCHEMBL20437025 0.77 CRBN (0.47) ALDH1A1TDP1DDB1CRBN
SCHEMBL21946654 0.75 CRBN (0.53) ALDH1A1TDP1DDB1CRBN
SCHEMBL26043094 0.74 CRBN (0.34) DDB1CRBN
SCHEMBL26043102 0.74 CRBN (0.34) DDB1CRBN
SCHEMBL24891031 0.73 CRBN (0.45) ALDH1A1TDP1DDB1CRBNMAPT
SCHEMBL24891065 0.73 CRBN (0.45) ALDH1A1TDP1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11820781-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway NURIX THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed
US-20230227471-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY NURIX THERAPEUTICS, INC. 2023-07-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11820781-B2 Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway BTK, CBL, XIAP ALDH1A1 4172/4885KDM4E 1076/4885HPGD 3847/4885
US-20230227471-A1 BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY BTK, CBL, XIAP ALDH1A1 4172/4885KDM4E 1076/4885HPGD 3847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback